These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8856611)

  • 1. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis.
    Kavanaugh AF; Davis LS; Jain RI; Nichols LA; Norris SH; Lipsky PE
    J Rheumatol; 1996 Aug; 23(8):1338-44. PubMed ID: 8856611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis.
    Davis LS; Kavanaugh AF; Nichols LA; Lipsky PE
    J Immunol; 1995 Apr; 154(7):3525-37. PubMed ID: 7897232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
    Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
    J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
    Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
    J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
    Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
    Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.
    Barrera P; Blom A; van Lent PL; van Bloois L; Beijnen JH; van Rooijen N; de Waal Malefijt MC; van de Putte LB; Storm G; van den Berg WB
    Arthritis Rheum; 2000 Sep; 43(9):1951-9. PubMed ID: 11014344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody.
    Kavanaugh AF; Schulze-Koops H; Davis LS; Lipsky PE
    Arthritis Rheum; 1997 May; 40(5):849-53. PubMed ID: 9153545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
    Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J
    J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants.
    Scali JJ; Visentini S; Salomón J; Sevilla D; Ju YC; Morales E; Ugarte L; Tachdjian A; Pacheco G; Veiga S
    Ann N Y Acad Sci; 2007 Sep; 1110():389-401. PubMed ID: 17911454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.